Lakefront Biotherapeutics NV current report, Q1 FY2023

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in the metadata) for the month of January 2023. The filing serves to incorporate by reference a press release dated January 3, 2023, which is attached as Exhibit 99.1. The registrant is a foreign private issuer incorporated in Belgium.

Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing to distribute a press release and does not contain a financial statement or quantitative performance data within the provided text.

Material Changes

The filing does not detail material changes versus prior periods. It solely references the issuance of a press release on January 3, 2023, without summarizing the content of that release in the body of the Form 6-K.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or descriptions of unusual items. These details are presumed to be contained within the attached Exhibit 99.1 (the press release), which is not included in the input text.

Key Facts for Investor Verification

  • Verify the content of the press release dated January 3, 2023 (Exhibit 99.1), as the Form 6-K itself contains no substantive operational or financial details.
  • Confirm the registrant is Galapagos NV, a Belgian entity, rather than Lakefront Biotherapeutics NV.
  • Note that this filing incorporates the press release into multiple Registration Statements on Form S-8.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.